arsenic has been researched along with Osteogenic Sarcoma in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 16 (84.21) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, T; Li, Q; Nam, A; Rebhun, RB; Seo, KW; Youn, HY | 1 |
| Cai, W; He, P; Tan, M; Wang, B; Wu, B; Zhang, X | 1 |
| Hogg, PJ; Lu, H; Noy, JM; Stenzel, M; Yang, JL | 1 |
| Abematsu, M; Ishidou, Y; Komiya, S; Nagano, S; Nagao, H; Nakamura, S; Setoguchi, T; Yamamoto, T; Yokouchi, M | 1 |
| Bai, J; Gu, J; Li, R; Li, W; Li, X; Mu, Y; Wang, X; Wang, Y; Yue, Z; Zhang, H; Zhong, L | 1 |
| Abematsu, M; Fujimoto, Y; Ishidou, Y; Kitajima, S; Kitamoto, S; Komiya, S; Maeda, S; Nagano, S; Nagao-Kitamoto, H; Nagata, M; Nakamura, S; Setoguchi, T; Tsuru, A; Yamamoto, T; Yokouchi, M; Yonezawa, S; Yoshioka, T | 1 |
| Feng, L; Feng, T; Huang, Y; Qi, W; Qiao, G; Shen, Z; Yao, Y | 1 |
| Guo, L; Li, R; Li, W; Li, X; Mu, Y; Su, X; Wang, X; Wang, Z; Yue, Z; Zhang, H; Zhong, L | 1 |
| Chen, TY; Chen, ZG; Gao, X; Huang, CW; Huang, XC; Li, ZB; Maimaiti, XY; Zhang, L | 1 |
| Li, R; Mou, Y; Wang, X; Wang, Y; Wang, Z; Xia, J; Yue, Z; Zhang, H; Zhong, L | 1 |
| Furukawa, T; Ishidou, Y; Komiya, S; Maeda, S; Nagano, S; Nagao-Kitamoto, H; Nagata, M; Nakamura, S; Saitoh, Y; Setoguchi, T; Tanimoto, A; Tsuru, A; Yokouchi, M | 1 |
| Guo, W; Ji, T; Lu, X; Peng, C; Zhao, H | 1 |
| Changliang, P; Tingting, R; Wei, G; Xinchang, L; Yi, Y | 1 |
| Li, XH; Wang, WB; Yang, GF; Zhao, Z | 1 |
| Li, R; Li, Y; Shi, Y; Wang, Y; Wei, Y; Zhang, H | 1 |
| Chiu, HW; Ho, SY; Lin, W; Wang, YJ | 1 |
| Fang, JZ; Li, KH; Xiao, T | 1 |
| Guo, W; Tang, S; Tang, XD; Yang, Y | 1 |
| Li, WQ; Li, XS; Wang, WB | 1 |
19 other study(ies) available for arsenic and Osteogenic Sarcoma
| Article | Year |
|---|---|
Melarsomine suppresses canine osteosarcoma cell survival via inhibition of Hedgehog-GLI signaling.
Topics: Animals; Apoptosis; Arsenicals; Blotting, Western; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Dog Diseases; Dogs; Glycine; Glycine Agents; Hedgehog Proteins; Inhibitory Concentration 50; Osteosarcoma; Real-Time Polymerase Chain Reaction; Signal Transduction; Triazines; Zinc Finger Protein GLI1 | 2019 |
Arsenic trioxide induces autophagic cell death in osteosarcoma cells via the ROS-TFEB signaling pathway.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Metabolic Networks and Pathways; Osteosarcoma; Oxides; Reactive Oxygen Species | 2018 |
Direct Polymerization of the Arsenic Drug PENAO to Obtain Nanoparticles with High Thiol-Reactivity and Anti-Cancer Efficiency.
Topics: Antineoplastic Agents; Arsenicals; Cell Line, Tumor; Cell Proliferation; Drug Carriers; Humans; Mitochondria; Nanoparticles; Osteosarcoma; Polymerization; Polymers; Sulfhydryl Compounds | 2018 |
Arsenic trioxide prevents osteosarcoma growth by inhibition of GLI transcription via DNA damage accumulation.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA Damage; Hedgehog Proteins; Humans; Mice; Osteosarcoma; Oxides; Signal Transduction; Transcription Factors; Transcription, Genetic; Zinc Finger Protein GLI1 | 2013 |
Heme oxygenase-1 silencing increases the sensitivity of human osteosarcoma MG63 cells to arsenic trioxide.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; Bone Neoplasms; Cell Line, Tumor; DNA Primers; Gene Silencing; Heme Oxygenase-1; Humans; Osteosarcoma; Oxides; Polymerase Chain Reaction; Reactive Oxygen Species | 2014 |
GLI2 is a novel therapeutic target for metastasis of osteosarcoma.
Topics: Adolescent; Adult; Animals; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Child; Female; Hedgehog Proteins; Humans; Kruppel-Like Transcription Factors; Lung Neoplasms; Male; Mice; Neoplasm Invasiveness; Nuclear Proteins; Osteosarcoma; Oxides; Zinc Finger Protein Gli2 | 2015 |
Stathmin is key in reversion of doxorubicin resistance by arsenic trioxide in osteosarcoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Humans; Osteosarcoma; Oxides; RNA, Small Interfering; Stathmin | 2014 |
Silencing SATB1 inhibits the malignant phenotype and increases sensitivity of human osteosarcoma U2OS cells to arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Gene Expression; Gene Knockdown Techniques; Humans; Matrix Attachment Region Binding Proteins; Neoplasm Invasiveness; Osteosarcoma; Oxides; Phenotype; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering | 2014 |
Synergistic effects of arsenic trioxide combined with ascorbic acid in human osteosarcoma MG-63 cells: a systems biology analysis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Bone Neoplasms; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Humans; Osteosarcoma; Oxides; Systems Biology | 2014 |
Arsenic Trioxide Activate Transcription of Heme Oxygenase-1 by Promoting Nuclear Translocation of NFE2L2.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Nucleus; Gene Expression Regulation, Neoplastic; Heme Oxygenase-1; Humans; Immunohistochemistry; NF-E2-Related Factor 2; Osteosarcoma; Oxides; Transcription, Genetic | 2015 |
Combination of Hedgehog inhibitors and standard anticancer agents synergistically prevent osteosarcoma growth.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cisplatin; Doxorubicin; Drug Synergism; Hedgehog Proteins; Humans; Osteosarcoma; Oxides; Pyridines | 2016 |
Arsenic trioxide inhibits the growth of adriamycin resistant osteosarcoma cells through inducing apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glutathione; Glutathione Transferase; Humans; Inhibitory Concentration 50; Intracellular Space; Multidrug Resistance-Associated Proteins; Osteosarcoma; Oxides | 2010 |
Arsenic trioxide inhibits osteosarcoma cell invasiveness via MAPK signaling pathway.
Topics: Animals; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Humans; MAP Kinase Signaling System; Matrix Metalloproteinase 9; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Osteosarcoma; Oxides; Phosphorylation | 2010 |
Arsenic trioxide up-regulates Fas expression in human osteosarcoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; fas Receptor; Flow Cytometry; Humans; Osteosarcoma; Oxides; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Arsenic trioxide induces apoptosis of p53 null osteosarcoma MG63 cells through the inhibition of catalase.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Bone Neoplasms; Catalase; Cell Line, Tumor; Flow Cytometry; Glutathione; Humans; Osteosarcoma; Oxides; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Suppressor Protein p53 | 2012 |
Synergistic effects of arsenic trioxide and radiation in osteosarcoma cells through the induction of both autophagy and apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Catalase; Cell Line, Tumor; DNA Damage; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Osteosarcoma; Oxides; Polyethylene Glycols | 2011 |
[Experimental study on the apoptotic effect of arsenic trioxide on human osteosarcoma MG-63 cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Humans; Osteosarcoma; Oxides; Tumor Cells, Cultured | 2002 |
[Preliminary report of combination chemotherapy including Arsenic trioxide for stage III osteosarcoma and Ewing sarcoma].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Child; Etoposide; Female; Follow-Up Studies; Humans; Male; Osteosarcoma; Oxides; Paclitaxel; Sarcoma, Ewing; Treatment Outcome | 2006 |
Using targeted magnetic arsenic trioxide nanoparticles for osteosarcoma treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Biological Availability; Cisplatin; Drug Delivery Systems; Ferric Compounds; Ferrous Compounds; Humans; Kidney; Lactic Acid; Magnetics; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Transmission; Nanoparticles; Osteosarcoma; Oxides; Particle Size; Polyesters; Polymers; Rabbits; Random Allocation; Xenograft Model Antitumor Assays | 2007 |